2d6b80a758
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
- Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
15 lines
No EOL
1.6 KiB
Markdown
15 lines
No EOL
1.6 KiB
Markdown
# United States Preventive Services Task Force (USPSTF)
|
|
|
|
## Overview
|
|
Independent panel of national experts in prevention and evidence-based medicine that makes recommendations about clinical preventive services. USPSTF A/B recommendations trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans.
|
|
|
|
## Key Mechanism
|
|
USPSTF recommendations are the most powerful single policy lever for mandating coverage of preventive services in the US healthcare system. Grade A/B recommendations automatically trigger mandatory coverage requirements under the Affordable Care Act.
|
|
|
|
## Timeline
|
|
- **2018-09-18** — Published Grade B recommendation for adult obesity covering intensive multicomponent behavioral interventions (≥12 sessions in year 1); reviewed pharmacotherapy but declined to recommend due to insufficient maintenance data; therapeutic-dose GLP-1 agonists not yet available
|
|
- **2024** — Updated children and adolescents obesity recommendation (behavioral-only, did not address adult pharmacotherapy)
|
|
- **2026-04** — Adult obesity topic flagged as 'being updated' on website but redirect points toward cardiovascular prevention rather than GLP-1 pharmacotherapy; no formal petition for GLP-1 review publicly announced
|
|
|
|
## Policy Gap
|
|
As of April 2026, the 2018 recommendation remains operative despite substantial clinical evidence base for therapeutic-dose GLP-1 agonists (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) that could support an A/B rating. No formal nomination or petition process for GLP-1 pharmacotherapy review has been initiated. |